Shutting down the ALK-1 receptor inhibits the VEGF pathway. Response seen in patients who had used antiangiogenic therapy. VEGF therapies might work best in combination. SAN FRANCISCO — Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, tumor suppressor, angiogenesis, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, metastasis, European Organisation for Research and Treatment of Cancer, Dr. Filippo de Braud, antiangiogenesis, monoclonal antibody, VEGF therapy
Phenotypic platform better predicts cancer drug effectiveness from the lab to actual tumors. Platform reduces time and money spent on drugs that will not work or will be toxic. Platform removes researcher bias in choosing systems to target for drug discovery. SAN FRANCISCO — Researchers have created...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, Drug discovery, National Cancer Institute, NCI, angiogenesis, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, antiangiogenesis, phenotypic platform, Dr. Enrique Zudaire, cancer drug
VEGF and Ang2 are critical factors required for tumor angiogenesis. Combined blockade of VEGF and Ang2 with investigational agents enhances antitumor activity in preclinical studies. Combination of REGN910 with aflibercept warrants further clinical investigation. SAN FRANCISCO — Combining the investigational...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, angiogenesis, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, antiangiogenesis, antitumor, Ang2, Dr. Alshad S. Lalani, REGN910, aflibercept, combination therapy, VEGF, preclinical studies
SAN FRANCISCO — Progress in oncology drug development will take center stage Nov. 12-16, 2011, as thousands of scientists and industry experts convene at the Moscone Center West in San Francisco for the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. “During the last...
Posted to
News
by
AACR News
on
Thu, Nov 10 2011
Filed under:
Filed under: Press Releases, San Francisco, Research, Treatment, Breast Cancer, Conference, Cancer, teleconference, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, meeting, National Cancer Institute, NCI, angiogenesis, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, EORTC, Dr. Kenneth C. Anderson, European Organisation for Research and Treatment of Cancer, Dr. James H. Doroshow, Moscone Center West
CONFERENCE TO HIGHLIGHT ADVANCES IN CANCER DRUG DEVELOPMENT SAN FRANCISCO, CALIF., NOV. 12-16, 2011 What: The AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics will be held from Nov. 12-16, 2011, at the Moscone Center West in San Francisco. This unique conference combines...
Posted to
News
by
AACR News
on
Wed, Oct 5 2011
Filed under:
Filed under: Uncategorized, San Francisco, Treatment, Conference, melanoma, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, chemotherapy, Media Alerts, meeting, skin cancer, colon cancer, Molecular Targets and Cancer Therapeutics, non-small cell lung cancer, angiogenesis, squamous cell carcinoma, cancer drug development